SEMA3C and neoplasm: Among other class 3 semaphorins, SEMA3C has been found to be associated with tumor progression and poor prognosis across multiple tumor types, including pancreatic (8), gastric (9), prostate (10–12), and breast cancer (13–15), as well as glioma (16).